<document>
	<algorithm name = "VT version 5">
		<node>
			<name>
				Start Node
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Select One:
			</text>
			<childNodes>
				<childNode>
					<childName>
						DVT
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						PE
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				DVT
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Consider conducting baseline tests such Creatinine, PT, PTT, and possibly Bilirubin (AST/LT) to determine patient's condition.
			</text>
			<childNodes>
				<childNode>
					<childName>
						DVT Chooser
					</childName>
					<type>
						step
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				DVT Chooser
			</name>
			<ccdNodeName>
				patient_condition
			</ccdNodeName>
			<text>
				After baseline testing complete choose one option that best describes the patient's condition? (Choose one)
			</text>
			<childNodes>
				<childNode>
					<childName>
						Proximal DVT, Severely Symptomatic Distal DVT, Moderately Symptomatic Distal DVT
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Mildly Symptomatic DVT, Asymptomatic Distal DVT
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				Proximal DVT, Severely Symptomatic Distal DVT, Moderately Symptomatic Distal DVT
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Is there arterial compromise (phlegmasia albicans)?
			</text>
			<childNodes>
				<childNode>
					<childName>
						Massive DVT
					</childName>
					<type>
						No
					</type>
				</childNode>
				<childNode>
					<childName>
						Thrombolytic Therapy
					</childName>
					<type>
						Yes
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				Massive DVT
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Does the patient have a massive DVT?
			</text>
			<childNodes>
				<childNode>
					<childName>
                        No thrombolytic therapy
                    </childName>
					<type>
						No
					</type>
				</childNode>
				<childNode>
					<childName>
						Patient Bleed Risk
					</childName>
					<type>
						Yes
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
                No thrombolytic therapy
            </name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				No thrombolytic therapy suggested. Continue for anticoagulation information
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Patient Bleed Risk
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Is the patient's bleeding risk high or low?
			</text>
			<childNodes>
				<childNode>
					<childName>
						No thrombolytic therapy
					</childName>
					<type>
						high
					</type>
				</childNode>
				<childNode>
					<childName>
						Thrombolytic Therapy
					</childName>
					<type>
						low
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				Thrombolytic Therapy
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Consider thrombolytic therapy. Continue for anticoagulation information.
			</text>
			<childNodes>
				<childNode>
					<childName>
						Anticoagulation therapy
					</childName>
					<type>
						step
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				Anticoagulation therapy
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Is anticoagulation therapy safe for the patient?
			</text>
			<childNodes>
				<childNode>
					<childName>
						IVC Filter
					</childName>
					<type>
						No
					</type>
				</childNode>
				<childNode>
					<childName>
						GFR
					</childName>
					<type>
						Yes
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				IVC Filter
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Consider IVC Filter if the patient requires anticoagulation.
			</text>
			<childNodes>
			</childNodes>
		</node>
			
		<node>
			<name>
				Mildly Symptomatic DVT, Asymptomatic Distal DVT
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				No thrombolytic treatment suggested. Suggest a sequential Doppler ultrasound to determine if any blockages exist. Continue for anticoagulation information
			</text>
			<childNodes>
				<childNode>
					<childName>
						No thrombolytic therapy
					</childName>
					<type>
						step
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				PE
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Consider conducting baseline tests such as Creatinine, PT, PTT, and possibly Bilirubin(AST/LT) to determine patient's condition
			</text>
			<childNodes>
				<childNode>
					<childName>
						Hemodynamically stable
					</childName>
					<type>
						step
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				Hemodynamically stable
			</name>
			<ccdNodeName>
				null
			</ccdNodeName>
			<text>
				Is the patient hemodynamically stable?
			</text>
			<childNodes>
				<childNode>
					<childName>
						ECGTnt
					</childName>
					<type>
						No
					</type>
				</childNode>
				<childNode>
					<childName>
						Anticoagulation therapy
					</childName>
					<type>
						Yes
					</type>
				</childNode> 
			</childNodes>
		</node>
			
		<node>
			<name>
				ECGTnt
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Consider ECG and TnT to assess for myocardial damage
			</text>
			<childNodes>
				<childNode>
					<childName>
						Patient Bleed Risk
					</childName>
					<type>
						step
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				GFR
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Is the patient's GFR at least 30 mL/min?
			</text>
			<childNodes>
				<childNode>
					<childName>
						Choose anticoagulant1
					</childName>
					<type>
						Yes
					</type>
				</childNode>
				<childNode>
					<childName>
						Choose anticoagulant2
					</childName>
					<type>
						No
					</type>
				</childNode>
			</childNodes>
		</node>
			
		<node>
			<name>
				Choose anticoagulant1
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Choose an anticoagulant
			</text>
			<childNodes>
				<childNode>
					<childName>
						Intravenous Unfractionated Heparin with Warfarin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Subcutaneous Unfractionated Heparin with Warfarin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Low Molecular Weight Heparin - Dalteparin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Low Molecular Weight Heparin - Tinzaparin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Apixaban
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Dabigatran
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Edoxaban
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Rivaroxaban
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Fondaparinux
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				Intravenous Unfractionated Heparin with Warfarin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Intravenous Unfractionated Heparin with Warfarin:
- Consider administering intravenously following your institution specific protocol.
- Monitor anticoagulation with the PTT or anti factor Xa test using standard heparin dosing algorithm.
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Subcutaneous Unfractionated Heparin with Warfarin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Subcutaneous Unfractionated Heparin with Warfarin:
- Consider administering subcutaneously an initial dose of 333 units/kg followed by 250 units/kg twice daily
- No monitoring necessary
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Low Molecular Weight Heparin - Enoxaparin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Low Molecular Weight Heparin - Enoxaparin:
- Consider administering 1mg/kg of enoxaparin once daily, subcutaneously
- No routine monitoring required but consider for neonates, those with poor renal function, and those with body weight of less the 45kg or greater then 100kg
- Monitor anticoagulation with the anti factor Xa test
- Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Low Molecular Weight Heparin - Dalteparin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Low Molecular Weight Heparin - Dalteparin:
- Consider administering 200 units/kg of dalteparin once daily, subcutaneously
- No routine monitoring required but consider for neonates, those with poor renal function, and those with body weight of less then 45kg or greater then 100kg
- Monitor anticoagulation with the anti factor Xa test
-Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Low Molecular Weight Heparin - Tinzaparin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Low Molecular Weight Heparin - Tinzaparin:
- Consider administering 156 units/kg of dalteparin once daily, subcutaneously
- No routine monitoring required but consider for neonates, those with poor renal function, and those with body weight of less then 45kg or greater then 100kg
- Monitor anticoagulation with the anti factor Xa test
-Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Apixaban
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Apixaban:
- Consider initiating apixaban at 10mg twice daily for 1 week, ten 5mg twice daily
- No routine laboratory monitoring required but consider monitoring renal function if clinically indicated
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Dabigatran
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Dabigatran:
- Use LMWH, UFH, or Fondaparinux as monotherapy for 3 days before starting dabigatran
- If using LMWH, no monitoring required but consider for neonatesm those with poor renal function, and those with body weight of less then 45kg or granders then 100 kg.
- Monitor anticoagulation with the anti factor Xa test
-Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test
- If using UFH, monitor with the PTT or the anti-Xa using standard heparin dosing algorithm
- If using Fondaparinux, no monitoring required but consider monitoring renal function if clinically indicated
- After monotherapy consider initiating dabigatran at 150 mg twice daily
- This is the FDS approved dose for GFR greater then 30 mL/min
- No routine laboratory monitoring required but consider monitoring renal function if clinically indicated
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Edoxaban
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Edoxaban:
- Use LMWH, UFH, or Fondaparinux as monotherapy for 3 days before starting edoxaban
- If using LMWH, no monitoring required but consider for neonatesm those with poor renal function, and those with body weight of less then 45kg or granders then 100 kg.
- Monitor anticoagulation with the anti factor Xa test
-Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test
- If using UFH, monitor with the PTT or the anti-Xa using standard heparin dosing algorithm
- If using Fondaparinux, no monitoring required but consider monitoring renal function if clinically indicated
- After monotherapy consider initiating edoxaban at (need FDA insert for information)
- No routine laboratory monitoring required but consider monitoring renal function if clinically indicated
			</text>
			<childNodes>
			</childNodes>
		</node>	
		
		<node>
			<name>
				Rivaroxaban
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Rivaroxaban:
- Consider initiating rivaroxaban at 15mg daily for the first 3 weeks, then, 20mg daily
- No routine laboratory monitoring required but consider monitoring renal function if  clinically indicated
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Fondaparinux
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Fondaparinux:
- Consider administering by body weight: 5mg if less then 60kg, 7.5 mg if 60-100kh, and 10mg if greater the 100kg once daily, subcutaneously
- No routine laboratory monitoring required but consider monitoring renal function if clinically indicated
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node name = "Choose anticoagulant2" CCDNodeName = "Null">
			<name>
				Choose anticoagulant2
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Choose an anticoagulant
			</text>
			<childNodes>
				<childNode>
					<childName>
						Intravenous Unfractionated Heparin with Warfarin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Subcutaneous Unfractionated Heparin with Warfarin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
				<childNode>
					<childName>
						Low Molecular Weight Heparin with Warfarin
					</childName>
					<type>
						nameDecision
					</type>
				</childNode>
			</childNodes>
		</node>
		
		<node>
			<name>
				Intravenous Unfractionated Heparin with Warfarin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Intravenous Unfractionated Heparin with Warfarin:
- Consider administering intravenously following your institution specific protocol.
- Monitor anticoagulation with the PTT or anti factor Xa test using standard heparin dosing algorithm.
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Subcutaneous Unfractionated Heparin with Warfarin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Subcutaneous Unfractionated Heparin with Wargarin:
- Consider administering subcutaneously an initial dose of 333 units/kg followed by 250 units/kg twice daily
- No monitoring necessary
			</text>
			<childNodes>
			</childNodes>
		</node>
		
		<node>
			<name>
				Low Molecular Weight Heparin with Warfarin
			</name>
			<ccdNodeName>
				Null
			</ccdNodeName>
			<text>
				Low Molecular Weight Heparin with Warfarin:
- Consider administering 1mg/kg weight once a day, subcutaneously
- Monitor anticoagulation with the anti factor Xa test to target of 0.5 to 1.0
- Sample for monitoring must be collected 4 hours after injection for anti-factor Xa test.
			</text>
			<childNodes>
			</childNodes>
		</node>
	</algorithm>
</document>